Northern Trust’s Avenue Therapeutics ATXI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-12
Closed -$4K – 4768
2022
Q2
$4K Hold
12
– – ﹤0.01% 4732
2022
Q1
$7K Hold
12
– – ﹤0.01% 4711
2021
Q4
$13K Hold
12
– – ﹤0.01% 4735
2021
Q3
$21K Hold
12
– – ﹤0.01% 4608
2021
Q2
$35K Sell
12
-56
-82% -$276K ﹤0.01% 4521
2021
Q1
$467K Sell
68
-6
-8% -$41.2K ﹤0.01% 3833
2020
Q4
$492K Buy
74
+2
+3% +$10.5K ﹤0.01% 3732
2020
Q3
$877K Buy
72
+44
+157% +$535K ﹤0.01% 3444
2020
Q2
$334K Buy
28
+15
+115% +$169K ﹤0.01% 3634
2020
Q1
$130K Hold
13
– – ﹤0.01% 3768
2019
Q4
$140K Hold
13
– – ﹤0.01% 3873
2019
Q3
$87K Hold
13
– – ﹤0.01% 3947
2019
Q2
$92K Hold
13
– – ﹤0.01% 3982
2019
Q1
$69K Hold
13
– – ﹤0.01% 3993
2018
Q4
$79K Buy
+13
New +$62.2K ﹤0.01% 3970

Other funds holding ATXI

Northern Trust's ATXI Position: Q3 2022 in Review

Northern Trust sold out of Avenue Therapeutics (ATXI) in Q3 2022, closing a stake of 12 shares — an estimated $4K sold.

Northern Trust first reported a position in ATXI in Q4 2018 and held it in 15 quarters. The position peaked at $877K in Q3 2020. 10 funds tracked by Wall St. Rank hold ATXI as of Q3 2022.

  • Northern Trust reported no remaining Avenue Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Northern Trust sold 12 Avenue Therapeutics shares in Q3 2022, an estimated $4K.
  • Northern Trust first reported a position in Avenue Therapeutics in Q4 2018 and held it in 15 quarters.
  • Northern Trust's Avenue Therapeutics position peaked at $877K in Q3 2020.
  • 10 funds tracked by Wall St. Rank held Avenue Therapeutics as of Q3 2022.

Based on Northern Trust's 13F filing for Q3 2022, filed 14 Nov 2022.